Similarly experimentally induced paclitaxel resistance was associated with elevated IGF2 mRNA, while knockdown of IGF2, but not insulin-like growth factor 1 receptor (IGF1-R), restored sensitivity to paclitaxel in ovarian cancer cell lines [39]. The gene discussed is IGF2; the disease is ovarian carcinoma.